Asianet Newsable · Healthcare · 2026-08-21
CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel
The U.S. Food and Drug Administration’s target action date for Capricor’s biologics license application for Deramiocel is Saturday.
Read original on Asianet Newsable Get the app
Licensed summary · LicensedSummary
Related briefs
- Health 360: Maharashtra FDA cracks down on surrogate ads, unhealthy dining risks
- Background logic for FDA arguments to mandate folic acid fortification – Sanjeev Sabhlok blog
- SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
- Flies, cockroaches, stale food: FDA suspends licences of several Maharashtra outlets
- 5,414 Fined For Entering Divyangjan Coaches On Western Railway As Activists Demand Stricter Checks